Serum biomarkers are proteins generally
detected in urine, blood, and other bodily fluids produced by malignant
cells or in reaction to presence/absence of malignant cells. Preferably,
biomarkers should have at least one or more than one of the following
properties: prompt detection of cancer within high risk population,
diagnosis of specific type of cancer, prediction in its growth, screen
its treatment response, and detect early recurrence.
Several of the biomarkers are not precise
for organs or tumors and their levels may rise/decline in other
diseases. The diagnostic value of marker depends on the prevalence of a
disease in a selected population group or its percentage and sensitivity
in normal individuals in which negative results are obtained. The serum
biomarker is usually measured by its cost in a commonly available assay
with reproducible results in a sample which is easy to access. In the
past few years, the determination of serum biomarkers has been widely
accepted as an important tool for early diagnosis and to find
therapeutic solutions and projection of its growth in various kinds of
tumors.
The global serum biomarkers market is
projected to grow at a rapid pace in the next few years. Key drivers of
the market are increase in the number of people suffering from different
types of cancer and rise in the geriatric population. Increase in the
cancer-afflicted population is anticipated to be another key driver of
the market. According to a Centers for Disease Control and Prevention
(CDC) report, the number of cancer patients diagnosed in the U.S.
reached approximately 21 million in 2014. The number is expected to
increase to 25.4 million by 2024. Over 60% of the world’s new cancer
cases occur in Asia, Africa, and South America. Nearly the same
percentage of cancer deaths also take place in these regions. Stomach,
liver, lung, breast, and esophageal cancer are the most prevalent among
populations across the world. Each cancer type requires unique
treatment. Epidemiological studies predict variable incidences depending
on the region. Incidences are high in Pakistan, Brazil, India, and
France. Hence, rise in prevalence of cancer and the need for
personalized medicine are expected to drive demand for serum biomarkers.
This is likely to provide significant opportunities for players in this
market. However, rise in cost of surgeries and lack of reimbursement
policies in developing nations are expected to hamper the growth of the
global serum biomarkers market.
The global serum biomarkers market can be
segmented based on type of cancer and end-user. In terms of type of
cancer, the global market can be classified into hepatocellular
carcinoma, lung cancer, pancreatic & biliary tract cancer, breast
cancer, glioblastoma, and others. Based on end-user, the global serum
biomarkers market can be divided into hospitals, academic & research
institutes, ambulatory surgical centers, and others.
Geographically, the global serum
biomarkers market can be segmented into North America, Asia Pacific,
Latin America, Europe, and Middle East & Africa. The market in North
America is projected to expand at a high CAGR in the next few years.
This is attributed to the acceptance of better reimbursement policy
structure, and well-established health care system. Europe and Asia
Pacific are the other major markets for serum biomarkers. Rise in
investments in research and development by top players, presence of key
players, and collaboration of pharma & biotech companies with
academic & research institutes are the factors boosting the growth
of the serum biomarkers market in these regions.
Key players in the global serum
biomarkers market are Gilead, Boehringer Ingelheim GmbH, AstraZeneca,
Bristol-Myers Squibb, Novo Nordisk A/S, Novartis AG, Allergan, and
Pfizer, Inc.
The report offers a comprehensive
evaluation of the market. It does so via in-depth qualitative insights,
historical data, and verifiable projections about market size. The
projections featured in the report have been derived using proven
research methodologies and assumptions. By doing so, the research report
serves as a repository of analysis and information for every facet of
the market, including but not limited to: Regional markets, technology,
types, and applications.
No comments:
Post a Comment